<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Xbiotech Inc — News on 6ix</title>
    <link>https://6ix.com/company/xbiotech-inc</link>
    <description>Latest news and press releases for Xbiotech Inc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Tue, 18 Jun 2024 04:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/xbiotech-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835da6d78dffbe2df123730.webp</url>
      <title>Xbiotech Inc</title>
      <link>https://6ix.com/company/xbiotech-inc</link>
    </image>
    <item>
      <title>XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer</title>
      <link>https://6ix.com/company/xbiotech-inc/news/xbiotech-results-from-randomized-double-blinded-phase-12-study-suggest-potential-breakthrough-treatment-for-advanced-pancreatic-cancer</link>
      <guid isPermaLink="true">https://6ix.com/company/xbiotech-inc/news/xbiotech-results-from-randomized-double-blinded-phase-12-study-suggest-potential-breakthrough-treatment-for-advanced-pancreatic-cancer</guid>
      <pubDate>Tue, 18 Jun 2024 04:00:00 GMT</pubDate>
      <description>Findings Show Trends for Reduced Toxicities and Better Outcomes for Subjects Receiving ONIVYDE/5-FU Combination and Targeted anti-IL-1alpha Therapy AUSTIN,</description>
    </item>
    <item>
      <title>XBiotech to Begin Constructing New R&amp;D Facility on its 48-acre Campus</title>
      <link>https://6ix.com/company/xbiotech-inc/news/xbiotech-to-begin-constructing-new-randd-facility-on-its-48-acre-campus</link>
      <guid isPermaLink="true">https://6ix.com/company/xbiotech-inc/news/xbiotech-to-begin-constructing-new-randd-facility-on-its-48-acre-campus</guid>
      <pubDate>Thu, 04 Jan 2024 05:00:00 GMT</pubDate>
      <description>AUSTIN, Texas, Jan. 04, 2024 (GLOBE NEWSWIRE) -- XBiotech Inc. today announced that it plans to expand it’s campus headquarters with the construction of a</description>
    </item>
    <item>
      <title>XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke</title>
      <link>https://6ix.com/company/xbiotech-inc/news/xbiotech-announces-enrollment-completion-of-phase-i-clinical-trial-for-hutrukin-a-novel-candidate-therapy-for-stroke</link>
      <guid isPermaLink="true">https://6ix.com/company/xbiotech-inc/news/xbiotech-announces-enrollment-completion-of-phase-i-clinical-trial-for-hutrukin-a-novel-candidate-therapy-for-stroke</guid>
      <pubDate>Tue, 26 Sep 2023 04:00:00 GMT</pubDate>
      <description>AUSTIN, Texas, Sept. 26, 2023 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) Announces that Hutrukin is being developed by XBiotech as a breakthrough</description>
    </item>
    <item>
      <title>XBiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic Cancer</title>
      <link>https://6ix.com/company/xbiotech-inc/news/xbiotech-announces-enrollment-completion-of-phase-ii-placebo-controlled-multicenter-study-for-natrunix-in-pancreatic-cancer</link>
      <guid isPermaLink="true">https://6ix.com/company/xbiotech-inc/news/xbiotech-announces-enrollment-completion-of-phase-ii-placebo-controlled-multicenter-study-for-natrunix-in-pancreatic-cancer</guid>
      <pubDate>Wed, 30 Aug 2023 04:00:00 GMT</pubDate>
      <description>AUSTIN, Texas, Aug. 30, 2023 (GLOBE NEWSWIRE) -- XBiotech Inc. announced today completion of enrollment of the Phase II portion of its 1-BETTER study—a Phase</description>
    </item>
    <item>
      <title>XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical Trial</title>
      <link>https://6ix.com/company/xbiotech-inc/news/xbiotech-announces-first-patient-begins-novel-natrunix-therapy-in-phase-ii-rheumatoid-arthritis-ra-clinical-trial</link>
      <guid isPermaLink="true">https://6ix.com/company/xbiotech-inc/news/xbiotech-announces-first-patient-begins-novel-natrunix-therapy-in-phase-ii-rheumatoid-arthritis-ra-clinical-trial</guid>
      <pubDate>Tue, 08 Aug 2023 04:00:00 GMT</pubDate>
      <description>AUSTIN, Texas, Aug. 08, 2023 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) today began treating the first patient in a phase II, double-blind,</description>
    </item>
    <item>
      <title>XBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its Shares</title>
      <link>https://6ix.com/company/xbiotech-inc/news/xbiotech-commences-tender-offer-to-purchase-up-to-dollar80000000-worth-of-its-shares</link>
      <guid isPermaLink="true">https://6ix.com/company/xbiotech-inc/news/xbiotech-commences-tender-offer-to-purchase-up-to-dollar80000000-worth-of-its-shares</guid>
      <pubDate>Wed, 17 May 2023 04:00:00 GMT</pubDate>
      <description>AUSTIN, Texas, May 17, 2023 (GLOBE NEWSWIRE) -- Xbiotech Inc. (NASDAQ: XBIT) (“Xbiotech”) announced today that it commenced a “modified Dutch auction” issuer</description>
    </item>
    <item>
      <title>XBiotech Announces First Subject Enrollment in Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke</title>
      <link>https://6ix.com/company/xbiotech-inc/news/xbiotech-announces-first-subject-enrollment-in-phase-i-clinical-trial-for-hutrukin-a-novel-candidate-therapy-for-stroke</link>
      <guid isPermaLink="true">https://6ix.com/company/xbiotech-inc/news/xbiotech-announces-first-subject-enrollment-in-phase-i-clinical-trial-for-hutrukin-a-novel-candidate-therapy-for-stroke</guid>
      <pubDate>Mon, 17 Apr 2023 04:00:00 GMT</pubDate>
      <description>Hutrukin, A Therapy Discovered and Manufactured at XBiotech, Is Aimed to Reduce Brain Injury after StrokeAUSTIN, Texas, April 17, 2023 (GLOBE NEWSWIRE) --</description>
    </item>
    <item>
      <title>XBiotech Announces First Patient Enrolled into the French National Cancer Institute (INCA) Sponsored Phase I/II/III Clinical Study for Natrunix™ Therapy for Colorectal Cancer</title>
      <link>https://6ix.com/company/xbiotech-inc/news/xbiotech-announces-first-patient-enrolled-into-the-french-national-cancer-institute-inca-sponsored-phase-iiiiii-clinical-study-for-natrunixtm-therapy-for-colorectal-cancer</link>
      <guid isPermaLink="true">https://6ix.com/company/xbiotech-inc/news/xbiotech-announces-first-patient-enrolled-into-the-french-national-cancer-institute-inca-sponsored-phase-iiiiii-clinical-study-for-natrunixtm-therapy-for-colorectal-cancer</guid>
      <pubDate>Thu, 13 Oct 2022 04:00:00 GMT</pubDate>
      <description>INCA funded Phase I/II/III Study for Natrunix in Combination with Trifluridine/Tipiracil, the TASKIN Study, Launches at 20 Leading Medical Centers in France</description>
    </item>
    <item>
      <title>XBiotech Announces Successful Completion of Phase I portion of Pancreatic Cancer Study</title>
      <link>https://6ix.com/company/xbiotech-inc/news/xbiotech-announces-successful-completion-of-phase-i-portion-of-pancreatic-cancer-study</link>
      <guid isPermaLink="true">https://6ix.com/company/xbiotech-inc/news/xbiotech-announces-successful-completion-of-phase-i-portion-of-pancreatic-cancer-study</guid>
      <pubDate>Mon, 20 Jun 2022 04:00:00 GMT</pubDate>
      <description>Novel Natrunix Treatment Shows Promise in Combination Chemotherapy for Treatment of Pancreatic CancerAUSTIN, Texas, June 20, 2022 (GLOBE NEWSWIRE) -- XBiotech</description>
    </item>
    <item>
      <title>XBiotech Announces French National Agency (ANSM) Approval and National Cancer Institute (INSA) funding to Support Phase I/II/III Clinical Study for Natrunix™ in Combination with Trifluridine/Tipiracil (TASKIN) for Treatment of Metastatic Colorectal Cancer</title>
      <link>https://6ix.com/company/xbiotech-inc/news/xbiotech-announces-french-national-agency-ansm-approval-and-national-cancer-institute-insa-funding-to-support-phase-iiiiii-clinical-study-for-natrunixtm-in-combination-with-trifluridinetipiracil-taskin-for-treatment-of-metastatic-colorectal-cancer</link>
      <guid isPermaLink="true">https://6ix.com/company/xbiotech-inc/news/xbiotech-announces-french-national-agency-ansm-approval-and-national-cancer-institute-insa-funding-to-support-phase-iiiiii-clinical-study-for-natrunixtm-in-combination-with-trifluridinetipiracil-taskin-for-treatment-of-metastatic-colorectal-cancer</guid>
      <pubDate>Thu, 28 Apr 2022 04:00:00 GMT</pubDate>
      <description>ANSM approves NATRUNIX for INSA funded Phase-I-III Study at 20 Leading Medical Centers in FranceAUSTIN, Texas, April 28, 2022 (GLOBE NEWSWIRE) -- XBiotech</description>
    </item>
    <item>
      <title>XBiotech Inks Clinical Manufacturing Deal</title>
      <link>https://6ix.com/company/xbiotech-inc/news/xbiotech-inks-clinical-manufacturing-deal</link>
      <guid isPermaLink="true">https://6ix.com/company/xbiotech-inc/news/xbiotech-inks-clinical-manufacturing-deal</guid>
      <pubDate>Wed, 02 Feb 2022 05:00:00 GMT</pubDate>
      <description>XBiotech Manufacturing Antibody Drug for Janssen Research &amp; Development, LLC (Janssen), One of the Janssen Pharmaceutical Companies of Johnson &amp;</description>
    </item>
    <item>
      <title>XBiotech Announces First Patient Enrolled in Phase I Clinical Trial for Novel Arthritis Therapy Natrunix-SQ</title>
      <link>https://6ix.com/company/xbiotech-inc/news/xbiotech-announces-first-patient-enrolled-in-phase-i-clinical-trial-for-novel-arthritis-therapy-natrunix-sq</link>
      <guid isPermaLink="true">https://6ix.com/company/xbiotech-inc/news/xbiotech-announces-first-patient-enrolled-in-phase-i-clinical-trial-for-novel-arthritis-therapy-natrunix-sq</guid>
      <pubDate>Wed, 26 Jan 2022 05:00:00 GMT</pubDate>
      <description>Natrunix-SQ, A True Human Antibody Therapy Discovered and Manufactured at XBiotech, Is Aimed as a Breakthrough Treatment for Arthritic DiseaseAUSTIN, Texas,</description>
    </item>
    <item>
      <title>FDA Approves XBiotech’s IND in Rheumatology</title>
      <link>https://6ix.com/company/xbiotech-inc/news/fda-approves-xbiotechs-ind-in-rheumatology</link>
      <guid isPermaLink="true">https://6ix.com/company/xbiotech-inc/news/fda-approves-xbiotechs-ind-in-rheumatology</guid>
      <pubDate>Mon, 13 Dec 2021 05:00:00 GMT</pubDate>
      <description>Launching Novel True Human Antibody Therapy Natrunix™ to Treat Rheumatology AUSTIN, Texas, Dec. 13, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT)</description>
    </item>
    <item>
      <title>XBiotech to Launch Novel Candidate Therapy for Stroke</title>
      <link>https://6ix.com/company/xbiotech-inc/news/xbiotech-to-launch-novel-candidate-therapy-for-stroke</link>
      <guid isPermaLink="true">https://6ix.com/company/xbiotech-inc/news/xbiotech-to-launch-novel-candidate-therapy-for-stroke</guid>
      <pubDate>Thu, 28 Oct 2021 04:00:00 GMT</pubDate>
      <description>Company Commencing Phase I/II Study to Test Safety and Efficacy of its New Drug Candidate to Reduce Brain Injury After StrokeAUSTIN, Texas, Oct. 28, 2021</description>
    </item>
    <item>
      <title>Dr. Benjamin Musher to Chair Phase 1-2 Study Evaluating XBiotech’s Natrunix™ Anti-Cancer Therapy in Pancreatic Cancer</title>
      <link>https://6ix.com/company/xbiotech-inc/news/dr-benjamin-musher-to-chair-phase-1-2-study-evaluating-xbiotechs-natrunixtm-anti-cancer-therapy-in-pancreatic-cancer</link>
      <guid isPermaLink="true">https://6ix.com/company/xbiotech-inc/news/dr-benjamin-musher-to-chair-phase-1-2-study-evaluating-xbiotechs-natrunixtm-anti-cancer-therapy-in-pancreatic-cancer</guid>
      <pubDate>Wed, 08 Sep 2021 04:00:00 GMT</pubDate>
      <description>AUSTIN, Texas, Sept. 08, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) (“XBiotech”) today announced that Benjamin Musher M.D., will chair XBiotech’s</description>
    </item>
    <item>
      <title>XBiotech Announces Addition of Dr. Mark Ziats, M.D. Ph.D. as Medical Director</title>
      <link>https://6ix.com/company/xbiotech-inc/news/xbiotech-announces-addition-of-dr-mark-ziats-md-phd-as-medical-director</link>
      <guid isPermaLink="true">https://6ix.com/company/xbiotech-inc/news/xbiotech-announces-addition-of-dr-mark-ziats-md-phd-as-medical-director</guid>
      <pubDate>Mon, 30 Aug 2021 04:00:00 GMT</pubDate>
      <description>Dr. Ziats Joins Clinical Team Involved in Launch and Management of Clinical Studies Across Multiple IndicationsAUSTIN, Texas, Aug. 30, 2021 (GLOBE NEWSWIRE)</description>
    </item>
    <item>
      <title>XBiotech Announces Payment of Dividend to Holders of Common Stock</title>
      <link>https://6ix.com/company/xbiotech-inc/news/xbiotech-announces-payment-of-dividend-to-holders-of-common-stock</link>
      <guid isPermaLink="true">https://6ix.com/company/xbiotech-inc/news/xbiotech-announces-payment-of-dividend-to-holders-of-common-stock</guid>
      <pubDate>Fri, 30 Jul 2021 04:00:00 GMT</pubDate>
      <description>Company distributed USD $75 Million to ShareholdersAUSTIN, Texas, July 30, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) (“XBiotech”) has completed</description>
    </item>
    <item>
      <title>XBiotech Announces Dividend to Holders of Common Stock</title>
      <link>https://6ix.com/company/xbiotech-inc/news/xbiotech-announces-dividend-to-holders-of-common-stock</link>
      <guid isPermaLink="true">https://6ix.com/company/xbiotech-inc/news/xbiotech-announces-dividend-to-holders-of-common-stock</guid>
      <pubDate>Tue, 06 Jul 2021 04:00:00 GMT</pubDate>
      <description>AUSTIN, Texas, July 06, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc.’s (NASDAQ: XBIT) (“XBiotech”) Board of Directors has declared an extraordinary cash dividend of</description>
    </item>
    <item>
      <title>XBiotech Announces Receipt of $75 Million from Sale of Antibody</title>
      <link>https://6ix.com/company/xbiotech-inc/news/xbiotech-announces-receipt-of-dollar75-million-from-sale-of-antibody</link>
      <guid isPermaLink="true">https://6ix.com/company/xbiotech-inc/news/xbiotech-announces-receipt-of-dollar75-million-from-sale-of-antibody</guid>
      <pubDate>Wed, 30 Jun 2021 04:00:00 GMT</pubDate>
      <description>Company Has Now Received a Total of $750 million for Sale of Its True Human Antibody AUSTIN, Texas, June 30, 2021 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT)</description>
    </item>
    <item>
      <title>XBiotech Announces First Patient Enrolled in Clinical Trial Evaluating XB2001 for the Treatment of Pancreatic Cancer</title>
      <link>https://6ix.com/company/xbiotech-inc/news/xbiotech-announces-first-patient-enrolled-in-clinical-trial-evaluating-xb2001-for-the-treatment-of-pancreatic-cancer</link>
      <guid isPermaLink="true">https://6ix.com/company/xbiotech-inc/news/xbiotech-announces-first-patient-enrolled-in-clinical-trial-evaluating-xb2001-for-the-treatment-of-pancreatic-cancer</guid>
      <pubDate>Wed, 23 Jun 2021 04:00:00 GMT</pubDate>
      <description>XB2001 Is a Novel Therapy that Interrupts Inflammation to Potentially Block Growth and Spread of Tumors and to Reduce Toxicity of Chemotherapy</description>
    </item>
  </channel>
</rss>